Zoldonrasib Earns FDA Breakthrough Therapy Designation in KRAS G12D+ NSCLC
The FDA has granted breakthrough therapy designation to zoldonrasib (RMC-9805), an investigational RAS(ON) KRAS G12D inhibitor, as a treatment for adults with locally...
Dual-Antibody Approach Advances Treatment of Extramedullary Multiple Myeloma
New study findings from Mayo Clinic found that a readily available dual-antibody therapy can produce strong and lasting responses in extramedullary multiple myeloma,...
New Breakthrough to Restore Aging Joints Could Help Treat Osteoarthritis :...
A study in mice by researchers from Stanford University has traced the loss of cartilage that comes with aging to a single protein, pointing...
Scientists ‘rejuvenate’ human eggs in breakthrough for IVF treatment
Your support helps us to tell the storyFrom reproductive rights to climate change to Big Tech, The Independent is on the ground when the...
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with...
FDA Grants Breakthrough Status to Zoldonrasib in Lung Cancer
Revolution Medicines announced in a news release that the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to zoldonrasib for adult...
Bepirovirsen Shows Breakthrough Potential for Functional Cure in Chronic Hepatitis B
In the pivotal phase 3 global, multi-center, randomized, double-blind, placebo-controlled B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), bepirovirsen (GSK) demonstrated a statistically significant...
What Were The Key Kidney and Bladder Cancer Advances in 2025?
What Were The Key Kidney and Bladder Cancer Advances in 2025?
Source link
Recent advances in CAR-NK cell therapy could revolutionze cancer treatment
Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained...
Zoldonrasib Nets Breakthrough Therapy Designation in KRAS G12D–Mutated NSCLC
The FDA has granted breakthrough therapy designation to zoldonrasib (RMC-9805-001) for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic...